Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

21 Roads to DollarLand

2018-2019
1.) SunGen ANDA #2 (Avatar) $1.6 Billion market 4 competitors: under FDA review
2.) SunGen ANDA #3 $1.6 Billion + market
3.) SequestOx® First ever Immediate Release ADF labeled opiod with ORAL, IV, and Nasal ADF Labeling (chewing) The Holy Grail of IR opioids
4.) Approval/Launch of First Ever Abuse Deterrent Generic Reformulated OxyContin® filed 09-20/2017
5.) First to market Generic ER 2 bead ADF Oxycodone ELI-201
6.) Unique Novel ADF without Naltrexone (new platform) which in 90% cheaper than the competitions ADFs
———————————————
7.) Huge Blockbuster Undisclosed NDA Approval
8.) Launch first four SunGen generics (2016) ($3 Billion combined markets) The two SunGen deals have a combined market worth $6 billion
9.) Buyout / Acquisition
10.) BP Partnership for entire ADF line
11.) Uplisting to NASDAQ exchange
12.) Merger
13.) Complete PH III trials for the first ever 24 hour
14.) Generic of Reformulated Opana® ER
15.) First ADF opiod for Chinese Pain Market --PuraCap/Humanwell
16.) Canadian Approval of SequestOx® - patents in place
17.) FDA accepts citizen petition urging the FDA to phase out oral prescription opioid analgesics that lack abuse-deterrent properties
18.) First ever generic Embeda®
19.) Launch additional 2017 SunGen generics brings the market to $6 billion
20.) Chinese approval of SequestOx® Chinese meeting Feb 2017
21.) European approval of AD oxycodone/opiod - patents in place


ELTP